Healthcare utilization and costs among patients with acromegaly in the United States

Aim: Recent evidence regarding the healthcare resource utilization (HCRU) and associated costs of acromegaly is limited. Materials & methods: This retrospective, cross-sectional administrative claims analysis (IQVIA Pharmetrics Plus^®) identified patients (≥18 years) with acromegaly between 1 January 2017 and 30 June 2022. HCRU and costs over 1 year were compared in patients with acromegaly and matched patients without acromegaly (age, sex, insurance type, year). Among patients with acromegaly, annual total healthcare costs of comorbidities and procedures consistent with high-risk comorbidities were reported. Costs were adjusted to 2023 USD. Results: Among 2289 patients with acromegaly and 2289 matched patients without acromegaly, mean age was 49.8 years and 51.6% were female. Patients with acromegaly had a significantly (p < 0.001) higher comorbidity burden than patients without acromegaly. A significantly (p < 0.001) greater proportion of patients with acromegaly versus patients without acromegaly had inpatient hospitalizations (20.1 vs 4.9%) and emergency department visits (23.9 vs 15.7%). Total mean healthcare costs were also significantly higher for patients with acromegaly than patients without acromegaly ($51,888 vs $10,601). The majority of acromegaly-related healthcare costs ($30,985) were attributable to acromegaly therapy ($25,895). Hypertension (42.8%) was the most common high-risk comorbidity associated with acromegaly. The costliest high-risk comorbidity was congestive heart failure, with a mean cost difference of $38,123 (p < 0.05) between patients with acromegaly with and without hypertension. Conclusion: Patients with acromegaly had higher HCRU and costs than matched patients without acromegaly, and the presence of acromegaly with high-risk comorbidities was associated with a substantial HCRU and cost burden. This high burden of illness may be alleviated with better disease control.